NCT05554666 - A Study of ASKG315 in Patients With Advanced Solid Tumors. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 15, 2022

Primary Completion Date

December 31, 2023

Study Completion Date

October 31, 2024

Conditions

Advanced Solid Tumors

Interventions

BIOLOGICAL

ASKG315

Injection with dose escalation stage of 3mg up to 45mg as well as dose expansion stage with recommended dose level from dose escalation stage.

Trial Locations (4)

NOT_YET_RECRUITING

Harbin Medical University Cancer Hospital, Harbin

RECRUITING

the First Affiliated Hospital of Nanchang University, Nanchang

RECRUITING

Shandong cancer hospital, Jinan

RECRUITING

Shanghai East Hospital, Shanghai